This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery

This study has been completed.
Public Health England
Information provided by:
Nabi Biopharmaceuticals Identifier:
First received: September 13, 2005
Last updated: December 26, 2007
Last verified: December 2007
Staphylococcus aureus (S. aureus) is the most common pathogen encountered in infections associated with orthopedic surgery. StaphVAX® is a bivalent S. aureus types 5 and 8 vaccine which contains the purified capsular polysaccharides that have been implicated as a major factor in the invasiveness of S. aureus. Immunoprophylaxis by vaccinating against S. aureus prior to surgery could provide sufficient antibody concentrations during surgery and the wound healing period so as to decrease the risk of S. aureus infection. This study aims to demonstrate the immunogenicity and safety of a single dose of StaphVAX in patients who are candidates for orthopedic surgery.

Condition Intervention Phase
Staphylococcal Infections Biological: S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate Biological: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adult Patients Receiving an Orthopedic Prosthetic Implant

Resource links provided by NLM:

Further study details as provided by Nabi Biopharmaceuticals:

Primary Outcome Measures:
  • Sero-type specific antibody concentrations [ Time Frame: 6 weeks after study dose ]

Secondary Outcome Measures:
  • Sero-type specific antibody concentrations [ Time Frame: various other time points after study dose, up to 26 wk ]
  • adverse events [ Time Frame: throughout 6 months observation after study dose ]

Enrollment: 67
Study Start Date: April 2005
Study Completion Date: August 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: vaccine
single dose
Biological: S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate
single IM dose of 200 mcg total conjugate
Other Name: StaphVAX®
Placebo Comparator: placebo
single dose
Biological: placebo
single dose IM


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 years or older
  • Candidate for knee or hip replacement
  • Expectation of protocol compliance
  • Negative pregnancy test, where appropriate

Exclusion Criteria:

  • Known S. aureus infection in the prior 3 months
  • Infection in the prior 2 weeks
  • Known HIV infection
  • Immunomodulatory drugs
  • Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early prostate cancer)
  • Hypersensitivity to components of StaphVAX
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00211965

United Kingdom
National Royal Orthopaedic Hospital
Stanmore, Middlesex, United Kingdom, HA7 4LP
Sponsors and Collaborators
Nabi Biopharmaceuticals
Public Health England
Study Director: Matt Hohenboken, MD, PhD Nabi Biopharmaceuticals
  More Information

Responsible Party: Matt Hohenboken, MD, PhD, Executive Director Clinical & Medical Affairs, Nabi Biopharmaceuticals Identifier: NCT00211965     History of Changes
Other Study ID Numbers: Nabi-1363
Study First Received: September 13, 2005
Last Updated: December 26, 2007

Keywords provided by Nabi Biopharmaceuticals:
Knee replacement surgery
hip replacement surgery
nosocomial infections

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections processed this record on September 21, 2017